AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15974833 — intervention group
Group type: EXPERIMENTAL
Intervention: PON1 192 BB and PON1 55 LL alleles
Number of subjects: 213
Study 12683740 — intervention group
Group type: EXPERIMENTAL
Intervention: UV photo intervention
Number of subjects: 144
Study 12683740 — intervention group
Group type: EXPERIMENTAL
Intervention: UV photo information
Number of subjects: 144
Study 12683740 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of UV photo and photoaging information
Number of subjects: 144
Study 10222548 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1 g/day
Number of subjects: 74
Study 10222548 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg qPM
Number of subjects: 74
Study 10222548 — intervention group
Group type: COMPARATOR
Intervention: Antacid
Number of subjects: 74
Study 8927743 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking 1-20 cigarettes per day
Number of subjects: 551
Study 8927743 — intervention group
Group type: COMPARATOR
Intervention: Nonsmoking females
Number of subjects: 551
Study 2064494 — intervention group
Group type: COMPARATOR
Intervention: Nutritional-hygienic intervention alone (placebo)
Number of subjects: 902
Study 2064494 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional-hygienic intervention plus antihypertensive medication (diuretic, beta-blocker, alpha 1-antagonist, calcium antagonist, or ACE inhibitor)
Number of subjects: 902
Study 2064494 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional-hygienic intervention
Number of subjects: 902
Study 6242795 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intraperitoneal insulin infusion (CIPII)
Number of subjects: 6
Study 6242795 — intervention group
Group type: COMPARATOR
Intervention: Continuous intravenous insulin infusion (CIVII)
Number of subjects: 6
Study 31087588 — intervention group
Group type: EXPERIMENTAL
Intervention: Nature soundscapes (easy to recognize)
Number of subjects: 0
Study 31087588 — intervention group
Group type: EXPERIMENTAL
Intervention: Nature soundscapes (hard to recognize)
Number of subjects: 0
Study 31087588 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban soundscapes (hard to recognize)
Number of subjects: 0
Study 31087588 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated artificial noises (similar properties to nature and urban sounds)
Number of subjects: 0
Study 30545918 — intervention group
Group type: EXPERIMENTAL
Intervention: Network switching
Number of subjects: 1003
Study 27300086 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal face-to-face interactions with human caregivers (mutual gaze and intermittent lip-smacking)
Number of subjects: 2
Study 27300086 — intervention group
Group type: COMPARATOR
Intervention: Additional handling (control group)
Number of subjects: 2
Study 27300086 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal face-to-face interactions with mothers
Number of subjects: 2
Study 25323890 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium phosphate (NaP) tablets
Number of subjects: 62
Study 25323890 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol (PEG) solution
Number of subjects: 62
Study 20734057 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotopically labeled water
Number of subjects: 200
Study 17604751 — intervention group
Group type: EXPERIMENTAL
Intervention: Super Size Me (experimental group, n=80)
Number of subjects: 135
Study 17604751 — intervention group
Group type: COMPARATOR
Intervention: Unrelated film (control group, n=55)
Number of subjects: 135
Study 18631958 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily
Number of subjects: 641
Study 18631958 — intervention group
Group type: COMPARATOR
Intervention: Donepezil 10 mg daily (background therapy)
Number of subjects: 641
Study 18631958 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging substudy
Number of subjects: 641
Study 15114097 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction (T-cell-depleting and interleukin-2 receptor antibodies)
Number of subjects: 174
Study 15114097 — intervention group
Group type: COMPARATOR
Intervention: Non-induction
Number of subjects: 174
Study 15114097 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction
Number of subjects: 174
Study 15114097 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell-depleting antibody induction
Number of subjects: 174
Study 15114097 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-interleukin-2 receptor antibodies
Number of subjects: 174
Study 11240440 — intervention group
Group type: EXPERIMENTAL
Intervention: Height (independent variable)
Number of subjects: 1284
Study 9302546 — intervention group
Group type: EXPERIMENTAL
Intervention: Concern about gaining weight due to quitting smoking
Number of subjects: 242
Study 8224951 — intervention group
Group type: COMPARATOR
Intervention: Argon laser treatment (ALT)
Number of subjects: 44
Study 8224951 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser treatment (DLT)
Number of subjects: 44
Study 3704568 — intervention group
Group type: EXPERIMENTAL
Intervention: terodiline
Number of subjects: 20
Study 3704568 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 3704568 — intervention group
Group type: EXPERIMENTAL
Intervention: terodiline withdrawal
Number of subjects: 20
Study 3704568 — intervention group
Group type: EXPERIMENTAL
Intervention: bladder training programme
Number of subjects: 20
Study 11180308 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum variance weights
Number of subjects: 0
Study 11180308 — intervention group
Group type: COMPARATOR
Intervention: Uniform weights
Number of subjects: 0
Study 11180308 — intervention group
Group type: COMPARATOR
Intervention: Cluster size weights
Number of subjects: 0
Study 11180308 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 0
Study 31063408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29510704 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Yoga (TY)
Number of subjects: 94
Study 29510704 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 94
Study 29510704 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 94
Study 27663118 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate TMS treatment (n=7)
Number of subjects: 10
Study 27663118 — intervention group
Group type: COMPARATOR
Intervention: Delayed TMS treatment (n=3)
Number of subjects: 10
Study 25420793 — intervention group
Group type: COMPARATOR
Intervention: Intradermal sodium stibogluconate (SSG)
Number of subjects: 87
Study 25420793 — intervention group
Group type: EXPERIMENTAL
Intervention: HF-EC followed by MWT with 0.045% DAC N-055
Number of subjects: 87
Study 25420793 — intervention group
Group type: EXPERIMENTAL
Intervention: MWT with 0.045% DAC N-055 in basic crème alone
Number of subjects: 87
Study 25420793 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 87
Study 25420793 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (HF-EC + DAC N-055)
Number of subjects: 87
Study 25420793 — intervention group
Group type: COMPARATOR
Intervention: Group I (SSG)
Number of subjects: 87
Study 25420793 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III (DAC N-055 alone)
Number of subjects: 87
Study 22396225 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 0
Study 22396225 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study 21410042 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-suction drain
Number of subjects: 112
Study 21410042 — intervention group
Group type: COMPARATOR
Intervention: Open (Penrose) drain
Number of subjects: 112
Study 17432693 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (Ginaton) 0.5 mg/kg
Number of subjects: 30
Study 17432693 — intervention group
Group type: COMPARATOR
Intervention: Control group (St. Thomas' cardioplegic solution only)
Number of subjects: 30
Study 17469410 — intervention group
Group type: EXPERIMENTAL
Intervention: Transendoscopic saline injection with or without epinephrine + coaptive bipolar electrocoagulation or heater probe
Number of subjects: 0
Study 17469410 — intervention group
Group type: EXPERIMENTAL
Intervention: Antisecretory agents at high doses
Number of subjects: 0
Study 17469410 — intervention group
Group type: EXPERIMENTAL
Intervention: Hp eradication
Number of subjects: 0
Study 17469410 — intervention group
Group type: COMPARATOR
Intervention: Argon plasma electrocoagulation
Number of subjects: 0
Study 17469410 — intervention group
Group type: COMPARATOR
Intervention: Mechanical methods such as endoclips or banding
Number of subjects: 0
Study 12190367 — intervention group
Group type: EXPERIMENTAL
Intervention: homocysteine-lowering therapy with folic acid (1 mg/d), vitamin B12 (400 micro g/d), and vitamin B6 (10 mg/d) (n = 272)
Number of subjects: 553
Study 12190367 — intervention group
Group type: EXPERIMENTAL
Intervention: homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6
Number of subjects: 553
Study 12190367 — intervention group
Group type: COMPARATOR
Intervention: placebo (n = 281)
Number of subjects: 553
Study 12190367 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 553
Study 10202868 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone (200 mg three times daily)
Number of subjects: 100
Study 10202868 — intervention group
Group type: COMPARATOR
Intervention: IM progesterone (50 mg daily)
Number of subjects: 100
Study 7795309 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcystein (NAC) administration as a bolus of 100 mg/kg followed by a continuous infusion of 20 mg/kg/h during cardiopulmonary bypass (CPB)
Number of subjects: 24
Study 7795309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2121769 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human IFN gamma (rhIFN gamma; 10(6) U/m2.day, im, 3 times/week) for 16 weeks
Number of subjects: 11
Study 101223 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 25 mg, 50 mg, and 100 mg twice daily
Number of subjects: 14
Study 101223 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg thrice daily
Number of subjects: 14
Study 101223 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol once daily
Number of subjects: 14
Study 101223 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol twice daily
Number of subjects: 14
Study 101223 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (once or twice daily)
Number of subjects: 14
Study 31506192 — intervention group
Group type: EXPERIMENTAL
Intervention: MomsTalkShots educational application
Number of subjects: 1103
Study 29534700 — intervention group
Group type: EXPERIMENTAL
Intervention: PEACH™ face-to-face program (1122 children, 919 families)
Number of subjects: 1513
Study 29534700 — intervention group
Group type: EXPERIMENTAL
Intervention: PEACH™ Online (391 children, 297 families)
Number of subjects: 1513
Study 29534700 — intervention group
Group type: COMPARATOR
Intervention: Pilot phase
Number of subjects: 1513
Study 29534700 — intervention group
Group type: COMPARATOR
Intervention: State-wide program
Number of subjects: 1513
Study 27599598 — intervention group
Group type: EXPERIMENTAL
Intervention: FSC 50/250 μg via Rotacaps/Rotahaler
Number of subjects: 0
Study 27599598 — intervention group
Group type: COMPARATOR
Intervention: FSC 50/250 μg via Diskus
Number of subjects: 0
Study 27599598 — intervention group
Group type: COMPARATOR
Intervention: FSC 50/250 μg via Rotacaps/Rotahaler and Diskus
Number of subjects: 0
Study 24147895 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg day(-1)) and zinc sulphate (220 mg day(-1))
Number of subjects: 83
Study 24147895 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg day(-1))
Number of subjects: 83
Study 24147895 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulphate (220 mg day(-1))
Number of subjects: 83
Study 24147895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 22209625 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (TRPV1 agonist)
Number of subjects: 56
Study 22209625 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamaldehyde (TRPA1 agonist)
Number of subjects: 56
Study 21144968 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 3687
Study 21144968 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 3687
Study 17920402 — intervention group
Group type: EXPERIMENTAL
Intervention: Preimplantation genetic screening (PGS)
Number of subjects: 0
Study 17920402 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 16268753 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease management
Number of subjects: 1069
Study 16268753 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented disease management
Number of subjects: 1069
Study 16268753 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 1069
Study 14525630 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapulmonary percussive ventilation (IPV) during nebulizer treatment
Number of subjects: 8
Study 14525630 — intervention group
Group type: COMPARATOR
Intervention: Assisted mucus clearance techniques without IPV
Number of subjects: 8
Study 14525630 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate, respiratory rate, oxyhemoglobin saturation, end‐tidal carbon dioxide, airway resistance, and peak expiratory flow
Number of subjects: 8
Study 10770541 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF (sargramostim) 250 microg subcutaneous injections three times per week for 24 weeks
Number of subjects: 309
Study 10770541 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF
Number of subjects: 309
Study 10770541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study 8644688 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 PUFA ethyl esters
Number of subjects: 20
Study 8644688 — intervention group
Group type: COMPARATOR
Intervention: olive oil (placebo)
Number of subjects: 20
Study 1900410 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous etidronate disodium (136 patients)
Number of subjects: 202
Study 1900410 — intervention group
Group type: COMPARATOR
Intervention: Saline alone (66 patients)
Number of subjects: 202
Study 6342458 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide, oxygen and halothane
Number of subjects: 0
Study 6342458 — intervention group
Group type: COMPARATOR
Intervention: Assisted ventilation, tracheal intubation with halothane and oxygen
Number of subjects: 0
Study 29851826 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at a single BL1 acupoint, 3 times per week for 8 weeks
Number of subjects: 120
Study 29851826 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears, 4 times per day for 8 weeks
Number of subjects: 120
Study 29851826 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 120
Study 29851826 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears
Number of subjects: 120
Study 27112319 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of Recurrence Therapy (FORT) intervention
Number of subjects: 144
Study 27112319 — intervention group
Group type: COMPARATOR
Intervention: Control group (structurally equivalent support group)
Number of subjects: 144
Study 24644301 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrupled semitendinosus tendon (ST) graft
Number of subjects: 135
Study 24644301 — intervention group
Group type: COMPARATOR
Intervention: Bone-patellar tendon-bone (BPTB) graft
Number of subjects: 135
Study 24644301 — intervention group
Group type: EXPERIMENTAL
Intervention: Meniscus resection
Number of subjects: 135
Study 24644301 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall OA prevalence
Number of subjects: 135
Study 22777592 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic lactobacilli vaginal tablets (L. brevis CD2, L. salivarius subsp. salicinius, L. plantarum)
Number of subjects: 159
Study 22777592 — intervention group
Group type: COMPARATOR
Intervention: Vaginal pH tablet (active comparator)
Number of subjects: 159
Study 22777592 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic lactobacilli vaginal tablets
Number of subjects: 159
Study 20099949 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Analysis System of Psychotherapy (CBASP) - 10-week intensive depression-focused intervention
Number of subjects: 257
Study 20099949 — intervention group
Group type: COMPARATOR
Intervention: Health and Wellness (HW) control
Number of subjects: 257
Study 17476489 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of isolated voluntary activation of TrA
Number of subjects: 22
Study 17476489 — intervention group
Group type: COMPARATOR
Intervention: Sit-up training to activate TrA in a non-isolated manner
Number of subjects: 22
Study 16167458 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic polypharmacy (APP)
Number of subjects: 0
Study 16167458 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 0
Study 12183688 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐amphetamine (30 mg oral dose)
Number of subjects: 34
Study 12183688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 9990363 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol (Dovonex) ointment (50 micrograms/g) twice daily for up to 3 months
Number of subjects: 306
Study 9990363 — intervention group
Group type: COMPARATOR
Intervention: Dithranol (Dithrocream) 0.1‐2% for up to 3 months
Number of subjects: 306
Study 8154531 — intervention group
Group type: EXPERIMENTAL
Intervention: Lodoxamide 0.1% ophthalmic solution
Number of subjects: 118
Study 8154531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 8154531 — intervention group
Group type: COMPARATOR
Intervention: Both treatment groups
Number of subjects: 118
Study 3419842 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of morphine (2 mg or 4 mg) and pentazocine (15 mg or 30 mg)
Number of subjects: 20
Study 3419842 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (2, 4, 8 or 16 mg)
Number of subjects: 20
Study 3419842 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine (15, 30 or 60 mg)
Number of subjects: 20
Study 3419842 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 20
Study 31639063 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose haMPCs (1.0 × 10^7 cells)
Number of subjects: 18
Study 31639063 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-dose haMPCs (2.0 × 10^7 cells)
Number of subjects: 18
Study 31639063 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose haMPCs (5.0 × 10^7 cells)
Number of subjects: 18
Study 31639063 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of haMPCs
Number of subjects: 18
Study 30077556 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.25 mg kg−1) prior to alfaxalone (0.5 mg kg−1)
Number of subjects: 33
Study 30077556 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfaxalone (0.5 mg kg−1) followed by midazolam (0.25 mg kg−1)
Number of subjects: 33
Study 30077556 — intervention group
Group type: COMPARATOR
Intervention: Normal saline IV prior to alfaxalone administration (Control group)
Number of subjects: 33
Study 30077556 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 33
Study 30077556 — intervention group
Group type: EXPERIMENTAL
Intervention: MA group
Number of subjects: 33
Study 27331352 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory support (mechanical ventilation or CPAP)
Number of subjects: 60
Study 27331352 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneously breathing infants
Number of subjects: 60
Study 27331352 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 60
Study 24613534 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable, single-size surgical-assist device
Number of subjects: 5
Study 22249781 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol plus standard care
Number of subjects: 150
Study 22249781 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 150
Study 19921230 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (8 IU)
Number of subjects: 86
Study 19921230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 17324531 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (Temodar) chemotherapy
Number of subjects: 0
Study 17324531 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 0
Study 17324531 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose escalation
Number of subjects: 0
Study 17324531 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical hypoxic cell sensitizers or carbon ion therapy
Number of subjects: 0
Study 15998892 — intervention group
Group type: COMPARATOR
Intervention: Placebo group of the Prostate Cancer Prevention Trial
Number of subjects: 18882
Study 15998892 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA cutoff values of 1.1, 2.1, 3.1, and 4.1 ng/mL
Number of subjects: 18882
Study 15998892 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA for detecting any prostate cancer
Number of subjects: 18882
Study 11982474 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned relaparotomy (PRL)
Number of subjects: 29
Study 11982474 — intervention group
Group type: COMPARATOR
Intervention: Primary abdominal closure
Number of subjects: 29
Study 9719123 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with mitomycin C and bleomycin (group B)
Number of subjects: 64
Study 9719123 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (group A)
Number of subjects: 64
Study 9719123 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with mitomycin C and bleomycin (group B) in oropharyngeal carcinoma
Number of subjects: 64
Study 9719123 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (group A) in oropharyngeal carcinoma
Number of subjects: 64
Study 9719123 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (as in arm B) in consecutive patients after December 1993
Number of subjects: 64
Study 7864317 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 30